UNICA IRIS Institutional Research Information System

SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 220.332
NA - Nord America 17.508
AS - Asia 2.914
AF - Africa 30
SA - Sud America 28
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 18
Totale 240.849
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 215.435
US - Stati Uniti d'America 17.395
CN - Cina 1.782
UA - Ucraina 1.715
SE - Svezia 1.125
DE - Germania 744
SG - Singapore 546
FI - Finlandia 507
GB - Regno Unito 372
TR - Turchia 177
VN - Vietnam 168
FR - Francia 125
CA - Canada 99
IN - India 77
NL - Olanda 76
KR - Corea 68
BE - Belgio 47
RU - Federazione Russa 41
IE - Irlanda 27
IR - Iran 24
HK - Hong Kong 20
JP - Giappone 19
EU - Europa 18
AT - Austria 15
AU - Australia 15
ES - Italia 14
PL - Polonia 14
BR - Brasile 13
RO - Romania 12
HR - Croazia 9
CZ - Repubblica Ceca 8
IS - Islanda 8
MX - Messico 8
CO - Colombia 7
CH - Svizzera 6
ID - Indonesia 6
JE - Jersey 6
TZ - Tanzania 6
CI - Costa d'Avorio 5
SK - Slovacchia (Repubblica Slovacca) 5
ZA - Sudafrica 5
BG - Bulgaria 4
CL - Cile 4
GR - Grecia 4
MU - Mauritius 4
MY - Malesia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
TH - Thailandia 4
BJ - Benin 3
BZ - Belize 3
IQ - Iraq 3
JO - Giordania 3
PE - Perù 3
PH - Filippine 3
SC - Seychelles 3
TW - Taiwan 3
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
EG - Egitto 2
IL - Israele 2
NO - Norvegia 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AR - Argentina 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
BS - Bahamas 1
HU - Ungheria 1
MO - Macao, regione amministrativa speciale della Cina 1
PA - Panama 1
TT - Trinidad e Tobago 1
Totale 240.849
Salva come PNG Salva come JPEG
Città #
Cagliari 214.128
Fairfield 2.638
Woodbridge 1.936
Chandler 1.562
Houston 1.353
Ashburn 1.259
Seattle 1.023
Wilmington 999
Cambridge 903
Jacksonville 887
Ann Arbor 830
Nyköping 830
Boardman 495
Dearborn 391
Nanjing 313
Singapore 255
Helsinki 249
Beijing 199
Uta 194
Boston 178
Dong Ket 166
Shanghai 154
Istanbul 150
San Diego 149
New York 139
Guangzhou 116
Shenyang 108
Milan 101
Krefeld 95
Nanchang 90
Rome 88
Hebei 85
Verona 82
Jiaxing 79
Toronto 73
Los Angeles 72
Changsha 64
Seoul 58
Tianjin 58
London 54
Norwalk 51
Bad Bellingen 49
Pune 48
Mountain View 47
Washington 45
Zhengzhou 44
Brussels 42
Orange 41
Redwood City 40
Jinan 38
Sassari 37
Phoenix 34
Amsterdam 32
Hefei 31
Wuhan 26
Hangzhou 25
Kunming 25
Ningbo 25
Shenzhen 24
Chicago 22
Redmond 20
Dublin 19
Atlanta 17
Falls Church 17
Saint Petersburg 17
Borås 15
Cedar Knolls 14
Leawood 14
Paris 14
Vienna 14
Hong Kong 13
Indiana 13
Taizhou 13
Kilburn 12
Montreal 12
San Francisco 12
Simaxis 12
Detroit 11
Edinburgh 11
Naples 11
Ankara 10
Berlin 10
Hounslow 10
San Mateo 10
West Lafayette 10
Wuxi 10
Augusta 9
Bari 9
Fuzhou 9
Islington 9
Zagreb 9
Chongqing 8
Miami 8
Reykjavik 8
Rio de Janeiro 8
Rockville 8
Torino 8
Chiswick 7
Naaldwijk 7
New Bedfont 7
Totale 233.784
Salva come PNG Salva come JPEG
Nome #
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib: preliminary results from a single prospective cohort study. 4.709
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 4.007
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.352
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer 3.081
BRAF-mutant colorectal cancer, a different breed evolving 3.060
Clustered protocadherins methylation alterations in cancer 3.042
null 3.029
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 2.939
Aspirin and cancer risk 2.892
Systemic therapy for the treatment of endometrial cancer 2.884
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 2.772
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib. Results from a single centre prospective cohort study. 2.719
Molecular-biology-driven treatment for metastatic colorectal cancer 2.531
Breast MRI: Clinical Indications, Recommendations, and Future Applications in Breast Cancer Diagnosis 2.479
Acetylsalicylic acid as a neo-adjuvant agent during preoperative chemoradiation for rectal cancer 2.475
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.442
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.424
CREAM study: Clinical correlation between ipilimumab-Related colitis And intestinal Microbiote in metastatic melanoma patients 2.364
Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report 2.288
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.242
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.167
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. 2.140
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.096
HYPOTHYROIDISM AND THYROID AUTOIMMUNITY AS A PROGNOSTIC BIOMARKER OF BETTER RESPONSE IN METASTATIC CANCER LONG SURVIVORS TREATED WITH SUNITINIB 2.094
Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? 2.094
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 2.076
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 2.054
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2.023
Gold nanoparticles: A new golden Era in oncology? 2.014
The abscopal effect in the era of cancer immunotherapy: a spontaneous synergism boosting anti-tumor immunity? 1.999
Health related quality of life in patients with onco-hematological diseases 1.997
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 1.989
Ipotiroidismo e autoimmunità tiroidea in pazienti affetti da carcinoma renale metastatico trattati con sunitinib con un follow-up di 30 mesi. 1.945
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of interleukin-6 1.909
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 1.860
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.792
Hypothyroidism and thyroid autoimmunity in metastatic renal cell carcinoma patients treated with sunitinib: 2 years follow-up of long survivors from a single centre experience. 1.791
From central to sentral (Serum angiogenesis central): Circulating predictive biomarkers to anti-VEGFR therapy 1.764
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study 1.736
Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer 1.627
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.552
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.482
New therapeutic targets in pancreatic cancer 1.450
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 1.429
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 1.396
The Quality of Life of People with Solid Cancer is Less Worse than Other Diseases with better Prognosis, Except in the Presence of Depression 1.392
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 1.366
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.336
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 1.324
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.309
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 1.287
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 1.277
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 1.247
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 1.224
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.215
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.184
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.169
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.163
Immunotherapy for colorectal cancer: where are we heading? 1.156
Cancer immunotherapy-associated hypophysitis 1.124
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 1.100
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 1.099
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 1.096
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials 1.091
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 1.081
null 1.080
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group 1.056
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.033
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 997
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 993
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 988
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world 983
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 945
Lactate dehydrogenase in hepatocellular carcinoma: something old, something new 937
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 913
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 898
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 886
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 880
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 855
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 853
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 848
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 845
FOLFOX or CAPOX in stage II to III colon cancer: Efficacy results of the italian three or six colon adjuvant trial 836
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 836
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 823
The role of fetal programming in human carcinogenesis - May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression? 800
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 797
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue 793
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 774
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 755
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 742
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 739
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 739
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 731
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 727
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 722
Aflibercept, a new way to target angiogenesis in the second line treatment of metastatic colorectal cancer (mCRC) 721
A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review 719
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 711
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 704
Totale 158.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 348.835
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 348.835
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202038.486 0 0 363 1.010 15.269 10.901 5.751 1.529 873 731 799 1.260
2020/202156.110 1.658 2.112 2.076 15.778 10.994 6.963 3.642 3.554 1.399 3.262 2.661 2.011
2021/202217.497 1.352 1.105 469 843 911 960 717 3.198 1.945 1.597 2.150 2.250
2022/202328.881 3.008 3.934 3.119 2.545 2.382 2.998 1.411 2.072 2.117 1.824 2.186 1.285
2023/202433.300 1.258 1.351 1.672 2.054 2.749 4.862 5.007 4.303 2.002 1.984 2.943 3.115
2024/202530.745 13.496 14.736 2.513 0 0 0 0 0 0 0 0 0
Totale 242.362